Summit Therapeutics said its closely tracked antibody, the first lung cancer drug to beat Merck’s Keytruda in a head-to-head ...

Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it ...

A recently-approved treatment could take a BiTE out of small cell lung cancer by using a person's own body to fight back.

Ivonescimab helped cut the risk of lung tumor progression in half in a multi-country Phase 3 trial. But it hasn’t yet clearly ...

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...

The new "liquid biopsy" test searches for tiny fragments of DNA that are shed by tumours into the bloodstream - it can ...

Merck (MRK) stock falls as the company withdraws U.S. marketing application for lung cancer therapy HER3-DXd developed with ...

“Lung cancer is a disease where uncontrolled cell growth occurs in the lung leading to tumours,” explains Dr Jenny Messenger, consultant in respiratory and general medicine at Nuffield Health Brighton ...

Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it ...